LY3002813

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for LY3002813, covering 2022-02-15 to 2024-10-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD [Phase 1]